• Home
  • Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study.

Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study.

Author List
Johnston SRD, Rugo HS, Tolaney SM, Munoz Fernandez M, Wei R, Martin M
Publication
Future oncology (London, England)
Publication ID (Profile URL)
https://researcherprofiles.org/profile/528310089
Publication Year
2024
PubMed ID
39023253
Publication Title
Johnston SRD, Rugo HS, Tolaney SM, Munoz Fernandez M, Wei R, Martin M. Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: a plain language summary of the monarchE study. Future Oncol. 2024; 20(28):2037-2048.